EYEN News and Press, Eyenovia Inc. From 08/07/23

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and developing the Optejet® device for use both in connection with its own drug-device t...

Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation Validates Eyenovia’s proprietary Optejet ® dispensing platform World-renowned board-certified ophthalmologist Dr. Nathan M. Radc...

2023-06-26 10:20:43 ET Eyenovia ( NASDAQ: EYEN ) was added to the small cap Russell 2000 and broad market Russell 3000 Indexes effective today, following the conclusion of the 2023 Russell indexes annual reconstitution. EYEN is -5.0% to $2.25 Source: Press ...

NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet ® device for use both in conn...

Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California NEW YORK, NY / ACCESSWIRE / June 6, 2023 / Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company commercia...

Presentation to highlight recent FDA approval of Mydcombi™ for mydriasis which leverages Eyenovia’s novel Optejet dispensing device Optejet represents the first true advancement in the topical administration of ophthalmic medications in more than 100 years NEW YORK, ...

2023-05-27 03:10:32 ET Summary I will update for my readers on the background of Eyenovia. I will give the readers an explanation of the need for their business model and the advantages it offers. I will share my perspective on the benefit of how the rollout of their approved ...

2023-05-11 22:17:06 ET Eyenovia, Inc. (EYEN) Q1 2023 Earnings Conference Call May 11, 2023, 16:30 ET Company Participants John Gandolfo - CFO & Secretary Michael Rowe - CEO & Director Bren Kern - COO & Corporate VP Conference Call Participants ...

2023-05-11 16:18:31 ET Eyenovia press release ( NASDAQ: EYEN ): Q1 GAAP EPS of -$0.15 beats by $0.04 . As of March 31, 2023, the Company’s cash and cash equivalents were approximately $18.5 million compared to $22.9 million as of December 31, 2022. For fur...

Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet ® Received feedback from FDA on its Phase 3 Microline presbyopia candidate that provides a clear and effici...